Immune Design Corporation

Former Medivation Inc. CEO David Hung is returning to oncology with the new cancer drug company Nuvation Bio Inc., which has raised $275m in series A venture capital and reassembled members of the t

Oncorus Inc. has closed a $79.5m series B round to initiate the first clinical trial for its herpes simplex-based oncolytic virus technology platform and select the first product candidate for its ot

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Novartis Takes Option On Nov

Investors recently have had major doubts about Immune Design Corp. ’s business prospects, but Merck & Co. Inc. apparently doesn’t, as it announced a planned tender Feb. 21 to acquire the vaccine bi